LLY vs ZURA
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. ZURA: Zura Bio is a clinical-stage biotechnology company pioneering bispecific antibody therapies to address significant unmet needs in complex autoimmune and inflammatory diseases.
Side-by-side fundamentals
| Metric | LLY | ZURA | Edge |
|---|---|---|---|
| Price as of 2026-09-09 close | $1,124.21 | $5.71 | |
| Market cap as of 2026-09-03 | $1.06T | $547M | |
| P/E as of 2026-09-03 | 37.73 | n/a | |
| PEG as of 2026-09-03 | 1.48 | -0.34 | ZURA lower |
| Net margin FY2025, SEC XBRL | +31.7% | n/a | |
| ROE FY2025, SEC XBRL | +77.8% | -67.6% | LLY higher |
| ROA FY2025, SEC XBRL | +18.4% | -60.2% | LLY higher |
| Debt / equity as of 2026-09-03 | 1.62 | 0.00 | ZURA lower |
| Revenue growth (YoY) as of 2026-09-03 | +49.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +31.7% | n/a | |
| Dividend yield as of 2026-09-03 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 10 | 0 | LLY higher |
| Beta as of 2026-09-03 | 0.55 | 1.44 | |
| 1-year return as of 2026-09-09 close | +49.8% | +159.5% | ZURA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.